We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
DARZALEX SC Janssen-Cilag Pty Ltd
Product name
DARZALEX SC
Sponsor
Accepted date
Jan-2025
Active ingredients
daratumumab
Proposed indication
DARZALEX SC is for the treatment of patients with newly-diagnosed multiple myeloma (a type of cancer that affects antibody-secreting cells) who are ineligible for a stem cell transplant. It is also used to treat high-risk smouldering multiple myeloma (a slow-growing version of multiple myeloma)
Application type
C (new indication)
Publication date
Jan-2025